TrialClinical and experimental medicine2025

Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial.

Huacong Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.